Drug Profile
Research programme: membrane lipid modulators - Laminar Pharmaceuticals
Alternative Names: LP-1810; LP-181T1; LP-182A1; LP-183A1; LP-183A2; LP-204A1; LP-205A1; LP-30171Latest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Lipopharma
- Developer Laminar Pharmaceuticals
- Class Anti-inflammatories; Antineoplastics; Cardiovascular therapies; Fatty acids
- Mechanism of Action Membrane lipid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Cardiovascular disorders; CNS disorders; Inflammation; Lipid metabolism disorders; Metabolic disorders
Most Recent Events
- 28 May 2023 No recent reports of development identified for preclinical development in CNS-disorders in Spain
- 28 May 2023 No recent reports of development identified for research development in Metabolic-disorders in Spain
- 28 Jun 2021 No recent reports of development identified for research development in Cancer in Spain